Vis enkel innførsel

dc.contributor.authorOlsen, Erik
dc.contributor.authorHolzhauer, Björn
dc.contributor.authorJulius, Stevo
dc.contributor.authorKjeldsen, Sverre
dc.contributor.authorLarstorp, Anne Cecilie Kjeldsen
dc.contributor.authorMancia, Giuseppe
dc.contributor.authorMehlum, Maria Hollund
dc.contributor.authorMo, Rune
dc.contributor.authorRostrup, Morten
dc.contributor.authorSøraas, Camilla Lund
dc.contributor.authorZappe, Dion H.
dc.contributor.authorWeber, Michael A.
dc.date.accessioned2021-10-13T05:58:59Z
dc.date.available2021-10-13T05:58:59Z
dc.date.created2021-01-15T16:50:56Z
dc.date.issued2021
dc.identifier.citationBlood Pressure. 2021, .en_US
dc.identifier.issn0803-7051
dc.identifier.urihttps://hdl.handle.net/11250/2789466
dc.description.abstractPurpose Event-based clinical outcome trials have shown limited evidence to support guidelines recommendations to lower blood pressure (BP) to <130/80 mmHg in middle-aged and elderly hypertensive patients with diabetes mellitus or with general high cardiovascular (CV) risk. We addressed this issue by post-hoc analysing the risk of CV events in patients who participated in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial and compared the hypertensive patients with type 2 diabetes mellitus with all high-risk hypertensive patients. Materials and methods Patients were divided into 4 groups according to the proportion of on-treatment visits before the occurrence of an event (<25% to ≥75%) in which BP was reduced to <140/90 or <130/80 mmHg. Patients with diabetes mellitus (n = 5250) were compared with the entire VALUE population with high CV risk (n = 15,245). Results After adjustments for baseline differences between groups, a reduction in the proportion of visits in which BP was reduced to <140/90 mmHg, but not to <130/80 mmHg, was accompanied by a progressive increase in the risk of CV morbidity and mortality as well as stroke, myocardial infarction and heart failure in both diabetes mellitus and in all high-risk patients. Target BP <130/80 mmHg reduced stroke risk in the main population but not in the diabetes mellitus patients. Patients with diabetes mellitus had higher event rates for the primary cardiac endpoint and all-cause mortality driven by a higher rate of heart failure. Conclusion In the high-risk hypertensive patients of the VALUE trial achieving more frequently BP <140/90 mmHg, but not <130/80 mmHg, showed principally the same protective effect on overall and cause-specific cardiovascular outcomes in patients with diabetes mellitus and in the general high-risk hypertensive population.en_US
dc.language.isoengen_US
dc.publisherTaylor & Francisen_US
dc.titleCardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus compared to all middle-aged and elderly hypertensive study patients with high cardiovascular risken_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionacceptedVersionen_US
dc.rights.holderThis is the authors' accepted manuscript to an article published by Taylor & Francis. Locked until 6.1.2022 due to copyright restrictions.en_US
dc.source.pagenumber0en_US
dc.source.journalBlood Pressureen_US
dc.identifier.doi10.1080/08037051.2020.1856642
dc.identifier.cristin1872372
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel